Lenalidomide vs Bortezomib Maintenance After Frontline Autologous Stem Cell Transplantation for Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Blood Cancer Journal
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Lenalidomide Versus Bortezomib Maintenance After Frontline Autologous Stem Cell Transplantation for Multiple Myeloma
Blood Cancer J 2021 Jan 07;[EPub Ahead of Print], MA Baertsch, EK Mai, T Hielscher, U Bertsch, HJ Salwender, M Munder, S Fuhrmann, U Dührsen, P Brossart, K Neben, J Schlenzka, C Kunz, MS Raab, J Hillengaß, A Jauch, A Seckinger, D Hose, S Luntz, P Sonneveld, H Lokhorst, H Martin, M Goerner, M Hoffmann, HW Lindemann, H Bernhard, IW Blau, C Scheid, B Besemer, KC Weisel, M Hänel, J Dürig, H GoldschmidtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.